Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2004 1
2007 1
2008 8
2009 13
2010 8
2011 12
2012 16
2013 4
2014 20
2015 9
2016 10
2017 9
2018 15
2019 9
2020 8
2021 11
2022 15
2023 15
2024 11
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
(E)-Methyl N'-(3-hy-droxy-benzyl-idene)hydrazinecarboxyl-ate dihydrate.
Li WW, Yu TM, Lv LP, Hu XC. Li WW, et al. Among authors: yu tm. Acta Crystallogr Sect E Struct Rep Online. 2011 Oct 1;67(Pt 10):o2584. doi: 10.1107/S1600536811035689. Epub 2011 Sep 14. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22058745 Free PMC article.
Necroptosis: A Pathogenic Negotiator in Human Diseases.
Chaouhan HS, Vinod C, Mahapatra N, Yu SH, Wang IK, Chen KB, Yu TM, Li CY. Chaouhan HS, et al. Among authors: yu tm. Int J Mol Sci. 2022 Oct 22;23(21):12714. doi: 10.3390/ijms232112714. Int J Mol Sci. 2022. PMID: 36361505 Free PMC article. Review.
N'-(3,4-Dihydroxy-benzyl-idene)acetohydrazide monohydrate.
Lv LP, Yu TM, Yu WB, Li WW, Hu XC. Lv LP, et al. Among authors: yu tm. Acta Crystallogr Sect E Struct Rep Online. 2009 Jul 18;65(Pt 8):o1897. doi: 10.1107/S1600536809027299. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21583587 Free PMC article.
N'-(3-Methoxy-benzyl-idene)aceto-hydrazide.
Lv LP, Yu TM, Yu WB, Li WW, Hu XC. Lv LP, et al. Among authors: yu tm. Acta Crystallogr Sect E Struct Rep Online. 2009 Jul 25;65(Pt 8):o1990. doi: 10.1107/S1600536809028864. Acta Crystallogr Sect E Struct Rep Online. 2009. PMID: 21583664 Free PMC article.
181 results